Diabetes News

Endocrinology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sourris KC et al. - A commonality among the chemically disparate compounds that inhibit the formation and accumulation of advanced glycation end products (AGEs) or their signalling pathways is their end organ protection in experimental models of diabetes complications. Although this group of therapeutics are structurally and functionally distinct with numerous mechanisms of action, the most important factor governing their therapeutic capability is clearly their ability to alleviate the tissue burden of advanced glycation, rather than the biochemical mechanism by which this is achieved.

Today in Diabetes...keeping you current

Altered resting state attentional networks in diabetic neuropathic pain
Journal of Neurology, Neurosurgery, and Psychiatry , 12/07/09

Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients
Journal of Nephrology, 12/06/09

Pregnancy in peri- and postmenopausal women: challenges in management
Menopause International, 12/06/09